世界の腫瘍免疫学市場予測:mAb、がんワクチン、 免疫チェックポイント阻害剤

◆英語タイトル:Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022
◆商品コード:DATA70125052
◆発行会社(リサーチ会社):RNCOS
◆発行日:2017年1月12日
◆ページ数:145
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Multi UserUSD6,000 ⇒換算¥672,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Currently, Immuno-oncology market has witnessed a high number of advancements. The competition between the players is intensifying. The biotechnology and pharmaceutical companies are striving to achieve first mover advantage by launching new and most effective therapies. This therapy is expected to be a game-changing approach to treating cancer.
The report “Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) – Global Forecast to 2022” provides a detailed analysis of the current and future market scenario of the global Immuno-oncology market with a brief overview of the industry. The report also provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global Immuno-oncology market.

According to this edition of the report, the Immuno-oncology market is anticipated to hit billions of dollars within the next 5-10 years. The report also provides the sales of major marketed Immuno-oncology drugs.

On the basis of type of product, the global Immuno-oncology market has been segmented into major product classes including monoclonal antibodies, therapeutic vaccines, and immune checkpoint inhibitors amongst others. According to the report, monoclonal antibodies segment was estimated to account for the largest share in 2016 due to rising prevalence of cancer & rising usage in a number of therapies (antibody-directed enzyme prodrug therapy and radio immunotherapy). Based on geography, the report divides the market into North America, Europe, and Asia-Pacific. In 2016, North America was estimated to account for the largest share.

Primarily, the Immuno-oncology market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immuno-oncology market. The report provides the market analysis of major indications along with the forecast till 2022.

Moreover, a major focus has been on the ongoing clinical trials for the development of innovative products. In this context, we have provided information about the Immuno-oncology programs at various stages of clinical development. The study also provides a comprehensive overview of various aspects of the clinical trials in the Immuno-oncology market, such as phases, and product type. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.

The latter part of the report discusses some of the prominent players in the Immuno-oncology market. Some of the key players dominant in the market are Amgen, Bristol-Myers Squibb, F. Hoffmann-La Roche, and Merck among others. A brief business overview of each player has been provided, along with their product and pipeline portfolios and recent developments.

Overall, Immuno-oncology is an important and rapidly emerging field, which deserves the attention it has been receiving in recent years; and thus the report will prove as a complete source of knowledge and analysis for clients and potential investors.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Immuno-Oncology: Overview
4. Market Drivers & Challenges
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
4.1.3 Growing Geriatric Population
4.1.4 High Healthcare Spending In Developed Economies
4.1.5 Strong Pipeline
4.1.6 Increasing Efficacy in a Wide Variety of Indications
4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
4.2 Challenges
4.2.1 Patent Expiry of Top-Selling Drugs
4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatments
4.2.3 Sky-High Development Costs of Cancer Immunotherapies
4.2.4 High Cost of Treatment
4.2.5 Lack of Awareness
4.3 Opportunities
4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
4.3.3 CAR-T Therapies: The Future of Cancer Care
4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies
5. Global Immuno-Oncology Market Outlook 2022
6. Global Immuno-Oncology Market, by Product Class
6.1 Monoclonal Antibodies (mAbs)
6.1.1 Naked Monoclonal Antibodies
6.1.1.1 Avastin (Bevacizumab)
6.1.1.2 Herceptin (Trastuzumab)
6.1.2 Conjugated Monoclonal Antibodies
6.1.2.1 ADCETRIS (Brentuximab vedotin)
6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)
6.1.3 Bispecific Monoclonal Antibodies
6.1.3.1 Blincyto (Blinatumomab)
6.1.4 Others
6.2 Therapeutic Vaccines
6.2.1 Provenge
6.2.2 Pediarix/ Infanrix
6.3 Immune Checkpoint Inhibitors
6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
6.3.1.1 Yervoy (Ipilimumab)
6.3.2 PD-1 and PD-L1 Inhibitors (Programmed Death 1 and Programmed Death Ligand
6.3.2.1 Opdivo (Nivolumab)
6.3.2.2 Keytruda (Pembrolizumab)
6.4 Others
7. Global Immuno-Oncology Market, By Major Indications
7.1 Head & Neck Cancer
7.2 Lung Cancer
7.3 Melanoma
7.4 Lymphoma
7.5 Leukemia
7.6 Others
8. Global Immuno-Oncology Market, By Geography
8.1 North America
8.2 Europe
8.3 Asia-Pacific
9. Trends & Developments
9.1 Lucrative Investment Trend
9.2 Emergence of Targeted and Combination Therapies
9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers
10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry
11. Pipeline Analysis of Immuno-Oncology
12. Competitive Landscape
12.1 Share of Major Players
13. Key Players Analysis
13.1 F. Hoffmann-La Roche AG
13.2 Johnson & Johnson
13.3 Amgen Inc.
13.4 Celgene Corporation
13.5 Bristol-Myers Squibb
13.6 Merck & Co., Inc.
13.7 Novartis
13.8 AstraZeneca Plc
13.9 Pfizer Inc
13.10 Eli Lilly and Company

List of Figures:

Figure 4-1: Global – Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global – Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global – Population above 60 Years (Billion), 2015 & 2050
Figure 5-1: Global – Immuno-Oncology Market (Billion US$), 2016-2022
Figure 6-1: Global – Share of Immuno-Oncology Market by Product (%), 2016
Figure 6-2: Global – Share of Immuno-Oncology Market by Product (%), 2022
Figure 6-3: Global – Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-4: Global – Avastin Market (Billion US$), 2012-2015
Figure 6-5: Global – Herceptin Market (Billion US$), 2012-2015
Figure 6-6: Global – ADCETRIS Market (Million US$), 2012-2015
Figure 6-7: Global – Kadcyla Market (Billion US$), 2013-2016
Figure 6-8: Global – Blincyto Market (Million US$), 2014-2016
Figure 6-9: Global – Other Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-10: Global – Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
Figure 6-11: Global – Provenge Market (Billion US$), 2012-2015
Figure 6-12: Global – Pediarix/ Infanrix Market (Billion US$), 2012-2014
Figure 6-13: Global – Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
Figure 6-14: Global – Yervoy Market (Million US$), 2012-2015
Figure 6-15: Global – Opdivo Market (Billion US$), 2014-2016
Figure 6-16: Global – Keytruda Market (Billion US$), 2014-2016
Figure 6-17: Global – Others Market (Billion US$), 2016-2022
Figure 7-1: Global – Share of Immuno-Oncology Market by Application (%), 2016
Figure 7-2: Global – Share of Immuno-Oncology Market by Application (%), 2022
Figure 7-3: Global – Head & Neck Cancer Market (Billion US$), 2016-2022
Figure 7-4: Head & Neck Cancer – Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-5: Head & Neck Cancer – Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-6: Global – Lung Cancer Market (Billion US$), 2016-2022
Figure 7-7: Lung Cancer – Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-8: Lung Cancer – Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-9: Global – Melanoma Market (Billion US$), 2016-2022
Figure 7-10: Melanoma – Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-11: Melanoma – Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-12: Global – Lymphoma Market (Billion US$), 2016-2022
Figure 7-13: Lymphoma – Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-14: Lymphoma – Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-15: Global – Leukemia Market (Billion US$), 2016-2022
Figure 7-16: Leukemia – Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-17: Leukemia – Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-18: Global – Other Cancer Market (Billion US$), 2016-2022
Figure 7-19: Other Cancer – Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-20: Other Cancer – Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 8-1: Global – Share of Immuno-Oncology Market by Geographic Regions (%), 2016
Figure 8-2: Global – Share of Immuno-Oncology Market by Geographic Regions (%), 2022
Figure 8-3: North America – Immuno-Oncology Market (Billion US$), 2016-2022
Figure 8-4: Europe – Immuno-Oncology Market (Billion US$), 2016-2022
Figure 8-5: Asia-Pacific – Immuno-Oncology Market (Billion US$), 2016-2022
Figure 9-1: Immuno-Oncology Funding by Product Type
Figure 9-2: Major Investors in Immuno-Oncology Market
Figure 9-3: Bristol-Myers Squibb and Merck & Co. – Strategic Collaborations
Figure 11-1: Global – Immuno-Oncology Pipeline Analysis by Product Type (%), 2016
Figure 11-2: Global – Immuno-Oncology Pipeline Analysis by Phase (%), 2016
Figure 12-1: Global – Share of Key Players in Immuno-Oncology Market (%), 2015
Figure 13-1: F. Hoffmann-La Roche AG – Sales by Business Segments (%), 2015
Figure 13-2: F. Hoffmann-La Roche AG – Pharmaceuticals Division Sales by Segments (%), 2015
Figure 13-3: F. Hoffmann-La Roche AG – Pharmaceuticals Division Sales by Geography (%), 2015
Figure 13-4: Johnson & Johnson – Sales by Business Segments (%), 2015
Figure 13-5: Johnson & Johnson – Sales by Pharmaceutical Segments (%), 2015
Figure 13-6: Johnson & Johnson – Sales by Geography (%), 2015
Figure 13-7: Amgen Inc. – Sales by Product (%), 2015
Figure 13-8: Amgen Inc. – Sales by Geography (%), 2015
Figure 13-9: Celgene Corporation – Sales by Products (%), 2015
Figure 13-10: Bristol Myers Squibb – Revenue by Business Segments (%), 2015
Figure 13-11: Bristol Myers Squibb – Oncology Division Revenue by Segments (%), 2015
Figure 13-12: Bristol Myers Squibb – Revenue by Geography (%), 2015
Figure 13-13: Merck & Co., Inc. – Revenue by Business Segments (%), 2015
Figure 13-14: Merck & Co., Inc. – Pharmaceutical Division Revenue by Segments (%), 2015
Figure 13-15: Merck & Co., Inc. – Revenue by Geography (%), 2015
Figure 13-16: Novartis – Sales by Business Segments (%), 2015
Figure 13-17: Novartis – Pharmaceuticals Division Sales by Segments (%), 2015
Figure 13-18: Novartis – Sales by Geography (%), 2015
Figure 13-19: AstraZeneca Plc – Revenue by Business Segments (%), 2015
Figure 13-20: AstraZeneca Plc – Oncology Division Revenue by Segments (%), 2015
Figure 13-21: AstraZeneca Plc – Revenue by Geography (%), 2015
Figure 13-22: Pfizer Inc – Revenue by Business Segments (%), 2015
Figure 13-23: Pfizer Inc – Revenue by Geography (%), 2015
Figure 13-24: Eli Lilly and Company – Revenue by Business Segments (%), 2015
Figure 13-25: Eli Lilly and Company – Human Pharmaceutical Division Revenue by Business Segments (%), 2015
Figure 13-26: Eli Lilly and Company – Revenue by Geography (%), 2015

List of Tables:

Table 6-1: Ongoing Trials for Avastin
Table 6-2: Ongoing Trials for Herceptin
Table 6-3: Ongoing Trials for ADCETRIS
Table 6-4: Ongoing Trials for Kadcyla
Table 6-5: Ongoing Trials for Blincyto
Table 6-6: Ongoing Trials for Other Monoclonal Antibodies
Table 6-7: Ongoing Trials for Provenge
Table 6-8: Ongoing Trials for Pediarix/ Infanrix
Table 6-9: Ongoing Trials for Yervoy
Table 6-10: Ongoing Trials for Opdivo
Table 6-11: Ongoing Trials for Keytruda
Table 6-12: Ongoing Trials for Other Immuno-Oncology Products
Table 7-1: Global – Oncology Incidence by Geography (‘000), 2015 & 2020
Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
Table 11-1: Global – Immuno-Oncology Product Pipeline
Table 13-1: F. Hoffmann-La Roche AG – Financials (Billion US$), 2013-2015
Table 13-2: F. Hoffmann-La Roche AG – Commercialized Immuno-Oncology Products
Table 13-3: F. Hoffmann-La Roche AG – Product Pipeline
Table 13-4: Johnson & Johnson – Financials (Billion US$), 2013-2015
Table 13-5: Johnson & Johnson – Commercialized Immuno-Oncology Products
Table 13-6: Johnson & Johnson – Product Pipeline
Table 13-7: Amgen Inc. – Financials (Billion US$), 2013-2015
Table 13-8: Amgen Inc. – Commercialized Immuno-Oncology Products
Table 13-9: Amgen Inc. – Product Pipeline
Table 13-10: Celgene Corporation – Key Financials (Million US$), 2013-2015
Table 13-11: Celgene Corporation – Commercialized Immuno-Oncology Products
Table 13-12: Celgene Corporation – Product Pipeline
Table 13-13: Bristol Myers Squibb – Key Financials (Million US$), 2013-2015
Table 13-14: Bristol Myers Squibb – Commercialized Immuno-Oncology Products
Table 13-15: Bristol Myers Squibb – Product Pipeline
Table 13-16: Merck & Co., Inc. – Key Financials (Million US$), 2013-2015
Table 13-17: Merck & Co., Inc. – Commercialized Immuno-Oncology Products
Table 13-18: Merck & Co., Inc. – Product Pipeline
Table 13-19: Novartis – Financials (Billion US$), 2013-2015
Table 13-20: Novartis – Commercialized Immuno-Oncology Products
Table 13-21: Novartis – Product Pipeline
Table 13-22: AstraZeneca Plc – Key Financials (Million US$), 2013-2015
Table 13-23: AstraZeneca Plc – Commercialized Immuno-Oncology Products
Table 13-24: AstraZeneca Plc – Product Pipeline
Table 13-25: Pfizer Inc – Key Financials (Billion US$), 2013-2015
Table 13-26: Pfizer Inc – Commercialized Immuno-Oncology Products
Table 13-27: Pfizer Inc – Product Pipeline
Table 13-28: Eli Lilly and Company – Key Financials (Million US$), 2013-2015
Table 13-29: Eli Lilly and Company – Commercialized Immuno-Oncology Products
Table 13-30: Eli Lilly and Company – Product Pipeline



【レポートのキーワード】

腫瘍免疫学、mAb、がんワクチン、 免疫チェックポイント阻害剤、癌治療、医療

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の腫瘍免疫学市場予測:mAb、がんワクチン、 免疫チェックポイント阻害剤(Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆